Oncolytic immunotherapy is an emerging class of cancer therapeutics that exploits the ability of viruses to selectively replicate in and kill tumors, while at the same time inducing a potent, patient-specific, anti-tumor immune response.
While oncolytic immunotherapies have shown clinical activity when given as single agents, we also expect these therapies to enhance the effectiveness of immune checkpoint blockade and thus become the second cornerstone of immuno-oncology approaches, moving beyond incremental improvement in cancer treatment to help more patients overcome their disease.
Replimune’s powerful Immulytic™ platform is intended to achieve the holy grail of personalized anti-cancer treatments — combining multiple mechanisms of action to deliver medicines with the ability to not only directly kill tumors and generate systemic anti-cancer immune responses, but also create a practical, in situ approach to achieving personalized systemic anti-cancer vaccination directly in the patient.
Our Immulytic™ platform consists of:
- A potent proprietary viral strain: We have engineered a newly-isolated strain of herpes simplex virus (HSV) that maximizes anti-tumor potency and selectivity, serving as the proprietary backbone for our therapeutics.
- Enhanced tumor killing and spread: Our therapies are armed with a fusogenic protein that further enhances cancer cell killing while also initiating powerful innate and adaptive immune responses.
- Delivery of potent immune-stimulating proteins: These therapies deliver additional proteins directly to tumors and draining lymph nodes to augment and potentiate an anti-tumor immune response.